{"id":"protease-inhibitor-ritonavir","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)"},{"rate":null,"effect":"Lipid abnormalities (elevated cholesterol and triglycerides)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL3182552","moleculeType":"Small molecule","molecularWeight":"720.96"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Protease inhibitors block the HIV protease enzyme, preventing the cleavage of viral polyproteins necessary for the production of infectious viral particles. Ritonavir is a potent cytochrome P450 inhibitor that dramatically increases the plasma concentration and half-life of the co-administered protease inhibitor, allowing for lower doses and improved dosing schedules. Together, they suppress HIV replication and reduce viral load in infected individuals.","oneSentence":"This combination inhibits HIV protease while ritonavir acts as a pharmacokinetic booster to increase protease inhibitor levels in the bloodstream.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:36.023Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT05587894","phase":"PHASE2","title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-04-27","conditions":"COVID-19, Immunodeficiency","enrollment":256},{"nctId":"NCT07406217","phase":"PHASE2","title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients","status":"RECRUITING","sponsor":"Calmy Alexandra","startDate":"2023-04-27","conditions":"COVID-19, Immunodeficiency","enrollment":256},{"nctId":"NCT07157007","phase":"PHASE2","title":"Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19","status":"RECRUITING","sponsor":"Traws Pharma, Inc.","startDate":"2025-09-16","conditions":"COVID - 19","enrollment":90},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT05605093","phase":"PHASE3","title":"Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2022-12-23","conditions":"COVID-19","enrollment":602},{"nctId":"NCT01935674","phase":"PHASE4","title":"Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2013-09","conditions":"HIV, Hypercholesterolaemia","enrollment":43},{"nctId":"NCT02652793","phase":"NA","title":"Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia","status":"COMPLETED","sponsor":"Judit Pich","startDate":"2015-11","conditions":"Human Immunodeficiency Virus","enrollment":31},{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":700},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT06676410","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants","status":"RECRUITING","sponsor":"Code Pharma","startDate":"2023-07-20","conditions":"HIV, HIV Infection","enrollment":40},{"nctId":"NCT02735863","phase":"PHASE2","title":"ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2016-05","conditions":"HIV Infection","enrollment":30},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05441215","phase":"PHASE1","title":"A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-12-12","conditions":"Healthy Participants","enrollment":8},{"nctId":"NCT05064800","phase":"PHASE1","title":"PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-21","conditions":"Healthy Participants","enrollment":24},{"nctId":"NCT03727152","phase":"PHASE3","title":"Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2019-05-01","conditions":"HIV","enrollment":170},{"nctId":"NCT03139630","phase":"","title":"COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients","status":"COMPLETED","sponsor":"Franck Boccara","startDate":"2016-03","conditions":"HIV Seropositivity, Dyslipidemias, PCSK9","enrollment":193},{"nctId":"NCT02437110","phase":"PHASE1","title":"HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2019-04-01","conditions":"Amyotrophic Lateral Sclerosis","enrollment":122},{"nctId":"NCT00056641","phase":"PHASE2","title":"Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-02-18","conditions":"HIV Infections","enrollment":328},{"nctId":"NCT02336074","phase":"PHASE2","title":"Research In Viral Eradication of HIV Reservoirs","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-11-27","conditions":"HIV","enrollment":60},{"nctId":"NCT00071760","phase":"PHASE2","title":"Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2003-10-23","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":59},{"nctId":"NCT01423812","phase":"PHASE4","title":"DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects","status":"COMPLETED","sponsor":"Ruth M. Rothstein CORE Center","startDate":"2012-01","conditions":"HIV","enrollment":60},{"nctId":"NCT00003008","phase":"PHASE2","title":"Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1997-12-15","conditions":"Sarcoma","enrollment":33},{"nctId":"NCT05779579","phase":"PHASE1, PHASE2","title":"Study of HS-10517 in Chinese Adult Participants","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2023-02-01","conditions":"COVID-19","enrollment":340},{"nctId":"NCT05545319","phase":"PHASE2","title":"A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2022-12-13","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised","enrollment":""},{"nctId":"NCT01156389","phase":"PHASE1","title":"Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2010-07","conditions":"Malaria","enrollment":34},{"nctId":"NCT04551261","phase":"PHASE1","title":"GLS4/RTV and TAF Drug-drug Interaction","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-01-10","conditions":"Chronic Hepatitis B","enrollment":28},{"nctId":"NCT05386433","phase":"EARLY_PHASE1","title":"Paxlovid in the Treatment of COVID-19 Patients With Uremia","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2022-06","conditions":"COVID-19, Uremia","enrollment":40},{"nctId":"NCT00885495","phase":"PHASE1, PHASE2","title":"Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2009-01","conditions":"HIV Infections","enrollment":17},{"nctId":"NCT04229290","phase":"PHASE4","title":"Second-line Switch to Dolutegravir Study","status":"COMPLETED","sponsor":"University of Nairobi","startDate":"2020-02-12","conditions":"HIV-1-infection","enrollment":795},{"nctId":"NCT02269917","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2015-03","conditions":"Human Immunodeficiency Virus Type 1","enrollment":1149},{"nctId":"NCT00006604","phase":"PHASE1, PHASE2","title":"Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-11","conditions":"HIV Infections","enrollment":195},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT00766597","phase":"PHASE1, PHASE2","title":"Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-08","conditions":"HIV Infections","enrollment":9},{"nctId":"NCT00001075","phase":"NA","title":"The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT00000892","phase":"NA","title":"A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00001091","phase":"PHASE1","title":"Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00001083","phase":"PHASE2","title":"Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":240},{"nctId":"NCT00000906","phase":"PHASE1","title":"Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":12},{"nctId":"NCT00038480","phase":"PHASE1","title":"Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":31},{"nctId":"NCT00012519","phase":"PHASE1, PHASE2","title":"Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":29},{"nctId":"NCT00028366","phase":"NA","title":"Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":56},{"nctId":"NCT00006152","phase":"PHASE2","title":"A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":42},{"nctId":"NCT00125983","phase":"PHASE2","title":"Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Pregnancy","enrollment":32},{"nctId":"NCT00001108","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT00027339","phase":"PHASE2","title":"Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":53},{"nctId":"NCT00039975","phase":"PHASE1","title":"Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Cardiovascular Diseases, Hypertension","enrollment":32},{"nctId":"NCT00036452","phase":"PHASE2","title":"A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":402},{"nctId":"NCT00004855","phase":"NA","title":"Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT00006339","phase":"PHASE2","title":"Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00001087","phase":"PHASE2","title":"The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00005762","phase":"NA","title":"Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-03","conditions":"HIV Infections","enrollment":90},{"nctId":"NCT00084058","phase":"PHASE1, PHASE2","title":"Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":26},{"nctId":"NCT00001133","phase":"PHASE1","title":"Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT00050895","phase":"PHASE3","title":"Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":775},{"nctId":"NCT00006144","phase":"PHASE2","title":"A Study of HIV-Disease Development in Aging","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-10","conditions":"HIV Infections","enrollment":90},{"nctId":"NCT00000822","phase":"PHASE1","title":"A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":46},{"nctId":"NCT00000859","phase":"NA","title":"A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1300},{"nctId":"NCT00000898","phase":"NA","title":"The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":18},{"nctId":"NCT00000914","phase":"NA","title":"A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":800},{"nctId":"NCT00000888","phase":"PHASE1","title":"Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Pregnancy","enrollment":14},{"nctId":"NCT00000952","phase":"PHASE1","title":"A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT00000924","phase":"PHASE2","title":"A Study to Compare Two Different Anti-HIV Drug Regimens","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00000941","phase":"PHASE1","title":"A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":56},{"nctId":"NCT00000940","phase":"PHASE2","title":"Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1999-05","conditions":"HIV Infections","enrollment":121},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT01232361","phase":"","title":"IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-10-08","conditions":"ADHD, HIV","enrollment":127},{"nctId":"NCT00243230","phase":"PHASE2","title":"Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09-19","conditions":"HIV Infections","enrollment":116},{"nctId":"NCT01276236","phase":"PHASE2","title":"Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2011-03-09","conditions":"Kaposi's Sarcoma","enrollment":13},{"nctId":"NCT03126370","phase":"PHASE4","title":"Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2018-01-08","conditions":"Hepatitis C, HIV Coinfection","enrollment":10},{"nctId":"NCT01068873","phase":"PHASE4","title":"Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)","status":"TERMINATED","sponsor":"Temple University","startDate":"2010-04","conditions":"HIV Infections","enrollment":1},{"nctId":"NCT00925756","phase":"PHASE4","title":"CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-10-20","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT02431975","phase":"PHASE4","title":"Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial","status":"COMPLETED","sponsor":"Columbia University","startDate":"2015-08","conditions":"HIV","enrollment":73},{"nctId":"NCT04311957","phase":"PHASE4","title":"Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults","status":"UNKNOWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2020-09-01","conditions":"HIV-1-infection, Antiretroviral Therapy","enrollment":386},{"nctId":"NCT00886990","phase":"","title":"Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-10","conditions":"HIV Infection, HIV Infections","enrollment":240},{"nctId":"NCT00887120","phase":"PHASE2","title":"Dose Reduction of Lopinavir in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT04418128","phase":"PHASE2, PHASE3","title":"Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia","status":"UNKNOWN","sponsor":"Gyeongsang National University Hospital","startDate":"2020-06-10","conditions":"Corona Virus Infection, COVID-19","enrollment":84},{"nctId":"NCT04391985","phase":"PHASE1, PHASE2","title":"Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":113},{"nctId":"NCT04378608","phase":"PHASE1, PHASE2","title":"Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-01-05","conditions":"Hepatitis C Virus Infection","enrollment":100},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT01148004","phase":"PHASE1","title":"The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2010-05-13","conditions":"HIV, Fenofibrate, Protease Inhibitors","enrollment":25},{"nctId":"NCT00307502","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-01","conditions":"HIV Infections","enrollment":675},{"nctId":"NCT01388543","phase":"PHASE4","title":"Genetics and HIV-1 Protease Inhibitors","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2006-09","conditions":"HIV","enrollment":31},{"nctId":"NCT02155101","phase":"PHASE3","title":"Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2014-05","conditions":"HIV/AIDS","enrollment":120},{"nctId":"NCT02531321","phase":"PHASE4","title":"Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2015-08","conditions":"Contraception, HIV","enrollment":17},{"nctId":"NCT00993031","phase":"PHASE3","title":"Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-12-15","conditions":"Malaria, HIV Infections","enrollment":389},{"nctId":"NCT02116660","phase":"PHASE2","title":"Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT00978068","phase":"PHASE3","title":"HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-09","conditions":"Malaria, HIV Infections","enrollment":176},{"nctId":"NCT00823979","phase":"PHASE2","title":"A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-03-25","conditions":"HIV-1","enrollment":105},{"nctId":"NCT00945282","phase":"PHASE2","title":"Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-10-20","conditions":"Infection, Human Immunodeficiency Virus","enrollment":8},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00608569","phase":"NA","title":"Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-03","conditions":"HIV Infections","enrollment":529},{"nctId":"NCT01923311","phase":"PHASE2, PHASE3","title":"Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-08-26","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":31},{"nctId":"NCT01351740","phase":"PHASE4","title":"Switch to Unboosted Atazanavir With Tenofovir Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-07","conditions":"HIV Infection","enrollment":50},{"nctId":"NCT01903031","phase":"PHASE2","title":"Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-12-30","conditions":"HIV-1 Infection","enrollment":84},{"nctId":"NCT00432783","phase":"","title":"A Comparison of Adherence Rates to Ritonavir and Its Accompanying Protease Inhibitor","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2006-06","conditions":"HIV Infections","enrollment":45},{"nctId":"NCT02926456","phase":"","title":"Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2016-07-22","conditions":"Human Immunodeficiency Virus","enrollment":337},{"nctId":"NCT00094523","phase":"PHASE3","title":"Fosamprenavir Versus Other Protease Inhibitors","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2004-12-14","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":314}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":175,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Protease Inhibitor/ritonavir","genericName":"Protease Inhibitor/ritonavir","companyName":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","companyId":"fundaci-n-fls-de-lucha-contra-el-sida-las-enfermedades-infecciosas-y-la-promoci","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits HIV protease while ritonavir acts as a pharmacokinetic booster to increase protease inhibitor levels in the bloodstream. Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}